Biochemical Failure After Radical Prostatectomy
The American Urological Association (AUA) defines biochemical recurrence after radical prostatectomy as an initial PSA value ≥ 0.2 ng/mL followed by a subsequent confirmatory PSA value ≥ 0.2 ng/mL. 1
Standard Definition
The AUA Prostate Cancer Guidelines Update Panel established this as the standardized definition for reporting surgical outcomes 2. This represents the consensus recommendation after reviewing 53 different variations of PSA progression definitions used in the literature 2.
Key Requirements:
- First PSA measurement: ≥ 0.2 ng/mL
- Confirmatory PSA measurement: ≥ 0.2 ng/mL (second value also ≥ 0.2 ng/mL)
- Timing of first postoperative PSA: Between 6 weeks and 3 months after surgery 2
- Date of failure: Defined as the date of the first detectable PSA level once confirmed 2
Important Clinical Context
This definition is for reporting outcomes only—it is NOT a threshold for initiating treatment 1, 2. The decision to start salvage therapy should be individualized based on multiple risk factors including Gleason score, pathological stage, surgical margins, and PSA kinetics 2.
Alternative Thresholds in the Literature:
While 0.2 ng/mL is the standard, the evidence shows:
- PSA ≥ 0.4 ng/mL followed by another increase may better predict metastatic relapse risk 1
- A cutpoint between 0.2-0.4 ng/mL appears most accurate for predicting clinical failure 2
- Lower values (0.2 ng/mL) increase sensitivity for detecting recurrence, while higher values (0.4 ng/mL) improve specificity 2, 3, 4
Research demonstrates that 62-86% of patients with PSA 0.2-0.3 ng/mL will experience subsequent PSA increases 3, 4, supporting the 0.2 ng/mL threshold's clinical relevance.
Timing Considerations for Salvage Therapy
For patients considering salvage radiation therapy, treatment should be provided when PSA is ≤ 0.5 ng/mL 5. For high-risk patients, salvage radiation may be offered when PSA is < 0.2 ng/mL 5. Earlier intervention at lower PSA levels is associated with:
- Improved biochemical control (5-year failure rates: 26.6% at PSA < 0.2 ng/mL vs. 57% at PSA 1.0-2.0 ng/mL) 5
- Better metastatic progression-free survival 5
- Lower prostate cancer-specific mortality 5
Common Pitfalls to Avoid
Do not use a single detectable PSA value to define biochemical failure—always obtain confirmatory testing to eliminate laboratory error 2
Wait at least 6 weeks post-surgery before obtaining the first PSA to allow adequate washout period 2
Do not confuse the definition of biochemical failure with treatment thresholds—a PSA of 0.2 ng/mL defines recurrence but does not automatically mandate salvage therapy 1, 2
Persistently elevated PSA at 6 weeks (≥ 0.1 ng/mL) after surgery indicates high risk for subsequent biochemical recurrence and warrants close monitoring 6